• Annually, influenza virus is contracted by approximately 1 billion people and causes serious illness in 3-5 million, with upward of 600,000 influenza-associated deaths, globally.
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• People with diabetes mellitus are at increased risk of complications from influenza, including disturbance of glycemic control, pneumonia, hospitalization, and mortality.² • Influenza vaccination can reduce complications,³ and guidelines from various health authorities recommend it annually for patients with diabetes, regardless of age.
2, [4] [5] • However, influenza vaccination rates in people living with diabetes remain suboptimal, below vaccination targets in many countries, when measured.
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• The reasons for suboptimal vaccination rates are highly varied and include patient factors, provider engagement, organizational factors, and social determinants.
• Previous research has shown that patients with diabetes are more likely to be vaccinated if they have additional risk factors, such as comorbid conditions. 7 Therefore, there may be value in learning from vaccination strategies in other high-risk populations.
Explore the benefits of influenza vaccination in the diabetes population and determine characteristics of successful vaccination programs in diabetes and other high-risk populations. Vaccination strategies in higher uptake populations, such as healthcare workers (where vaccination may be mandatory) and the elderly, were also reviewed.
• Six prospective or retrospective cohort or case-control studies on either type 1 or type 2 diabetes mellitus patients were accepted for meta-analysis to examine the impact of influenza vaccination on mortality and hospitalization.
• Meta-analysis showed that in unvaccinated patients with diabetes the rate of all-cause mortality was approximately 4%, with VE = 46% (95% CI 33 to 56%), I 2 = 79% ( Figure  1) . Hospitalization in unvaccinated patients with diabetes was 6%, with VE = 62% (95% CI, -23 to 88%), I 2 = 80% (Figure 2 ).
• Due to the diversity of study designs and the use of observational studies, the results of this analysis show between-study heterogeneity, and therefore provide only an approximate estimate of the impact of influenza vaccination on diabetes patients. There may be other factors that confound or moderate the results. For example, LooijmansVan den Akker et al. (2006) was the only study to report data for 18-65 year olds (all others were ≥65 years), but the number of cases were relatively small and therefore the estimate lacks precision.
• Mortality and hospitalization alone do not adequately capture the direct burden of influenza in patients with diabetes. All reasons for mortality or hospitalization were included, so the outcomes do not solely measure the impact of influenza infection. However, they are currently the best surrogate to measure the influenza complications in the existing literature.
• Noticeably absent from the literature are outcomes measuring any improvement in the direct burden on the patient, such as change in work productivity, diabetes-related complications not resulting in hospitalization, and incremental financial burden on the patient. This could be due to difficulty of capturing such information, or to the fact that the incremental change of that burden is not great against the backdrop of diabetes management overall. Nevertheless, it would seem to merit investigation.
• Cardiovascular complications related to influenza such as heart failure, myocardial infarction, or stroke and respiratory outcomes, such as pneumonia or respiratory failure, were sparsely reported and often only recorded if associated with hospitalization in the population of people living with diabetes. Hospitalization for diabetic ketoacidosis was reported in one study but was the only diabetes specific complication reported. No data were reported for work productivity or financial burden specifically ( Figure 3 • Despite a potential overlap with other chronic conditions where influenza vaccination is also recommended vaccination rates in diabetes mellitus are similar or slightly higher than these other conditions
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but nearly 50% of patients hospitalized for influenza related complications had a metabolic condition during the 2017-2018 flu season. (Figure 4) .
• Recent surveillance data on diabetes mellitus specifically was unavailable.
• After review of other high-risk populations, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] factors leading to high uptake of influenza vaccination that could be applied to diabetes patients included effective communication with the target population, standardized or mandatory vaccination policies and availability/accessibility of the vaccine ( Figure 5 ). • Evidence suggests that influenza vaccination is beneficial in reducing complications, hospitalizations, and mortality in the diabetes population and should be emphasized, especially considering its implications in alleviating a substantial societal economic burden.
• Patient history and vaccination status are not well captured along the patient journey, including hospitalization.
• Additional research is needed to observe and quantify the burden of influenza as impact on outcomes that directly affect the patient's daily life and self-care behavior, to optimally inform and tailor interventions and programs for flu vaccination in people living with diabetes.
• While there is evidence on the impact of high-risk population influenza vaccination campaigns, more research is needed to more deeply assess patient related factors that support flu vaccination uptake in the diabetes population specifically.
This study was funded by Sanofi. 
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• While influenza vaccination is still under target levels, the impact of vaccination has benefits from both an individual and societal perspective and should be an important focus of public health campaigns and patient care plans in diabetes mellitus.
• Further research is needed to review the direct burden influenza has on the patient. This research could be used to direct more targeted and effective influenza vaccination campaigns.
• Better and more uniform surveillance reporting on flu vaccination utilization and complications in chronic disease populations, including diabetes mellitus, is needed to fully understand the rates of vaccination and burden of influenza in these populations.
• Standardize data collection on vaccination status within the electronic health record (EHR) system at the point of ER visit, inpatient admission, and discharge to ensure complete and systematic collection of this information.
• Accessibility from both a physical and economic perspective and good communication with the target population have shown to be key factors for a successful vaccination campaigns in high risk groups, but further research is needed to explore application to diabetes mellitus populations specifically.
• Patient care protocols should include standing orders for vaccination to high risk populations, which would likely lead to increased vaccination utilization. 
Implications and Recommendations
